JP2022500443A5 - - Google Patents

Info

Publication number
JP2022500443A5
JP2022500443A5 JP2021514132A JP2021514132A JP2022500443A5 JP 2022500443 A5 JP2022500443 A5 JP 2022500443A5 JP 2021514132 A JP2021514132 A JP 2021514132A JP 2021514132 A JP2021514132 A JP 2021514132A JP 2022500443 A5 JP2022500443 A5 JP 2022500443A5
Authority
JP
Japan
Prior art keywords
abcb4
lnp
orf
formulated
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021514132A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500443A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/051172 external-priority patent/WO2020056370A1/en
Publication of JP2022500443A publication Critical patent/JP2022500443A/ja
Publication of JP2022500443A5 publication Critical patent/JP2022500443A5/ja
Pending legal-status Critical Current

Links

JP2021514132A 2018-09-13 2019-09-13 進行性家族性肝内胆汁うっ滞障害を処置するための修飾mRNA Pending JP2022500443A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862731055P 2018-09-13 2018-09-13
US62/731,055 2018-09-13
US201962840369P 2019-04-29 2019-04-29
US62/840,369 2019-04-29
PCT/US2019/051172 WO2020056370A1 (en) 2018-09-13 2019-09-13 Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders

Publications (2)

Publication Number Publication Date
JP2022500443A JP2022500443A (ja) 2022-01-04
JP2022500443A5 true JP2022500443A5 (cg-RX-API-DMAC7.html) 2022-09-26

Family

ID=69778403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514132A Pending JP2022500443A (ja) 2018-09-13 2019-09-13 進行性家族性肝内胆汁うっ滞障害を処置するための修飾mRNA

Country Status (6)

Country Link
US (1) US20220054653A1 (cg-RX-API-DMAC7.html)
EP (1) EP3863645A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022500443A (cg-RX-API-DMAC7.html)
AU (1) AU2019338557A1 (cg-RX-API-DMAC7.html)
CA (1) CA3111836A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020056370A1 (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
SG11201803360UA (en) 2015-10-22 2018-05-30 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
MX2021010075A (es) 2019-02-20 2021-12-10 Modernatx Inc Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales.
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
MX2021011031A (es) 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
CN111041025B (zh) 2019-12-17 2021-06-18 深圳市瑞吉生物科技有限公司 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法
CN118490818A (zh) 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
WO2021231503A2 (en) * 2020-05-11 2021-11-18 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for enhancing gene expression
CN111744019B (zh) * 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 基于甘露糖的mRNA靶向递送系统及其应用
EP3936946A1 (fr) 2020-07-10 2022-01-12 Patek Philippe SA Genève Oscillateur horloger a pivot flexible
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
EP4326227A1 (en) 2021-04-23 2024-02-28 ModernaTX, Inc. Stabilized formulations
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN115404273B (zh) * 2022-06-30 2023-06-23 湖南家辉生物技术有限公司 导致进行性家族性肝内胆汁淤积症ⅰ型的atp8b1基因突变体、蛋白和应用
EP4750895A1 (en) * 2023-07-26 2026-06-03 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating conditions associated with bsep deficiency
WO2025212858A1 (en) 2024-04-03 2025-10-09 Children's Hospital Medical Center Ivt messenger rna and methods of treating or preventing pfic type iv
CN119587504B (zh) * 2024-12-10 2025-11-14 华中科技大学同济医学院附属协和医院 一种靶向骨组织巨噬细胞的纳米颗粒及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012219B2 (en) * 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
PL2578685T3 (pl) * 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
WO2011025862A2 (en) * 2009-08-28 2011-03-03 Curna, Inc. Treatment of atp-binding cassette sub-family b member 1 (abcb1) related diseases by inhibition of natural antisense transcript to abcb1
US20140275229A1 (en) * 2012-04-02 2014-09-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1
EP2906697A4 (en) * 2012-10-15 2016-06-22 Ionis Pharmaceuticals Inc METHOD FOR MONITORING THE C9ORF72 EXPRESSION
WO2014160243A1 (en) * 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
CA2990883A1 (en) * 2015-06-30 2017-01-05 Ethris Gmbh Atp-binding cassette family coding polyribonucleotides and formulations thereof
EP3368089B1 (en) * 2015-10-26 2025-11-05 Translate Bio Ma, Inc. Nanoparticle formulations for delivery of nucleic acid complexes
DK3386484T3 (da) * 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
WO2017153936A1 (en) * 2016-03-10 2017-09-14 Novartis Ag Chemically modified messenger rna's
EP3458106A4 (en) * 2016-05-18 2020-03-18 Modernatx, Inc. POLYNUCLEOTIDS FOR CODING LIPOPROTEIN LIPASE FOR TREATING HYPERLIPIDEMIA
MX2019009070A (es) * 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.

Similar Documents

Publication Publication Date Title
JP2023105131A5 (cg-RX-API-DMAC7.html)
JP2021151238A5 (cg-RX-API-DMAC7.html)
JP2023116721A5 (cg-RX-API-DMAC7.html)
JP2023526975A5 (cg-RX-API-DMAC7.html)
JP2023052878A5 (cg-RX-API-DMAC7.html)
JP2020040981A5 (cg-RX-API-DMAC7.html)
JP2024026077A5 (cg-RX-API-DMAC7.html)
JP2023100643A5 (cg-RX-API-DMAC7.html)
JP2018531290A5 (cg-RX-API-DMAC7.html)
JP2016153424A5 (cg-RX-API-DMAC7.html)
JP2022116141A5 (cg-RX-API-DMAC7.html)
JP2023182571A5 (cg-RX-API-DMAC7.html)
JP2022538215A5 (cg-RX-API-DMAC7.html)
JP2023133317A5 (cg-RX-API-DMAC7.html)
JP2023509880A5 (cg-RX-API-DMAC7.html)
JP2022064180A5 (cg-RX-API-DMAC7.html)
JP2023116477A5 (cg-RX-API-DMAC7.html)
JP2020079331A5 (cg-RX-API-DMAC7.html)
JP2022518056A5 (cg-RX-API-DMAC7.html)
JP2023012502A5 (cg-RX-API-DMAC7.html)
JP2022122912A5 (cg-RX-API-DMAC7.html)
JP2022505925A5 (cg-RX-API-DMAC7.html)
JP2023084138A5 (cg-RX-API-DMAC7.html)
JP2023078173A5 (cg-RX-API-DMAC7.html)
JP2023159159A5 (cg-RX-API-DMAC7.html)